05 Feb, EOD - Indian

SENSEX 78271.28 (-0.40)

Nifty 50 23696.3 (-0.18)

Nifty Bank 50343.05 (0.37)

Nifty IT 42888.3 (0.07)

Nifty Midcap 100 54180.85 (0.68)

Nifty Next 50 64012.8 (0.65)

Nifty Pharma 21868.5 (0.62)

Nifty Smallcap 100 17108.5 (1.85)

05 Feb, EOD - Global

NIKKEI 225 38831.48 (0.09)

HANG SENG 20597.09 (-0.93)

S&P 6055.27 (0.21)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(12 Dec 2024, 15:51)

Aayush Wellness hit life high after bagging $3-mn order for healthcare and nutraceutical products

Aayush Wellness hit an upper circuit of 2% at Rs 180.55 after the company received a significant order worth $ 3 million from Cosmos Holdings, a leading distributor in Singapore, to supply various healthcare and nutraceutical products.


Under the terms of the agreement, the company will provide its flagship nutraceutical products to cater to Singapore’s growing demand for high-quality dietary supplements. These products include effervescent tablets, marine collagen, probiotics, super greens powders, and more. The supply will be delivered over the next year.

This order marks a significant milestone for Aayush Wellness Limited and marks its entry on a global nutraceuticals and healthcare market.

Singapore’s health supplements market is estimated to be worth US $ 202.8 million in 2024 and its annual growth rate is projected to be 3.81% p.a.

Naveena Kumar, managing director of the company said that “The success our product in India has laid foundation for the company’s foray into international markets, starting with Singapore a hub for health-conscious consumers. This is company’s first export order and mark’s the company entry in the premium Singaporean market. This shall have a substantial impact of the company operational performance and expansion plans by developing the export market for our products.”

Aayush Wellness is engaged provides health and wellness solutions. The company manufactures and exports nutraceuticals, supplements, healthy food, and enriching solutions by redefining typical practices.

The company reported standalone net profit of Rs 92 lakh in Q2 FY25 as against Rs 28 lakh posted in the Q2 FY24. Revenue from operations surged to Rs 14.28 lakh in Q2 FY25 as compared to Rs 60 lakh recorded in Q2 FY24.

The scrip hit an all time high of Rs 180.55 in intraday today. As of 12 December 2024, the company’s market capitalization stood at Rs 585.88 crore on the BSE.

More News
More Company News View Company Information

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +